文献速递造血干细胞移植与细胞治疗

阿仑单抗在儿童非恶性疾病异基因造血干细胞移植中的暴露-反应分析:ARTIC研究

Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study.
PubMed 文献 · Blood Adv · 2023-01-01

这项多中心研究在53例接受异基因造血干细胞移植的非恶性免疫或血液病患儿中建立阿仑单抗群体药代动力学模型,中位年龄4.4岁,中位累积剂量0.6 mg/kg。基于模型估算的移植日浓度中位数0.77 μg/mL将患儿分为低暴露组和高暴露组,高暴露与CD4+和CD8+ T细胞重建延迟(P<.0001)及移植失败风险增加(P=.043)相关。

要点

  • 阿仑单抗群体药代动力学模型纳入体重和基线淋巴细胞计数作为显著预测因子。
  • 移植日阿仑单抗浓度>0.77 μg/mL与CD4+和CD8+ T细胞重建延迟相关(P<.0001)。
  • 高阿仑单抗暴露与移植失败风险增加相关(P=.043),未显著影响≥2级aGVHD等。

核心结论

  • 该群体药代动力学模型适用于个体化静脉精准给药,以预测非恶性疾病儿童异基因造血干细胞移植中的阿仑单抗暴露,目标是在未来前瞻性研究中实现早期T细胞重建和预防移植失败。

研究设计与样本

  • 多中心研究,纳入53例接受异基因造血干细胞移植的非恶性免疫或血液病患儿,中位年龄4.4岁(IQR 0.8-8.7)。
  • 中位累积阿仑单抗剂量0.6 mg/kg(IQR 0.6-1),给药持续2至7天。
  • 采用非线性混合效应模型建立二室群体药代动力学模型,包含平行线性和非线性消除,以异速生长标度体重(中位17.50 kg,IQR 8.76-33.00)和基线淋巴细胞计数(均值2.24×10^9/L,标准差±1.87)为显著药代动力学预测因子。

主要发现

  • 基于模型估算的移植日中位浓度为0.77 μg/mL(IQR 0.33-1.82),据此将患者分为低暴露组(≤0.77 μg/mL)和高暴露组(>0.77 μg/mL)。
  • 移植日高阿仑单抗暴露与CD4+和CD8+ T细胞重建延迟相关(P<.0001)。
  • 高阿仑单抗暴露与移植失败风险增加相关(P=.043)。
  • 阿仑单抗暴露对≥2级aGVHD发生率、死亡率、1年嵌合状态、病毒再激活和自身免疫无显著影响,中位随访3.3年(IQR 2.5-8.0)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Alemtuzumab (anti-CD52 antibody) is frequently prescribed to children with nonmalignant diseases undergoing allogeneic hematopoietic stem cell transplantation (HSCT) to prevent graft failure (GF) and acute graft-versus-host disease (aGVHD). The aim of this multicenter study was the characterization of alemtuzumab population pharmacokinetics to perform a novel model-based exposure-response analysis in 53 children with nonmalignant immunological or hematological disease and a median age of 4.4 years (interquartile range [IQR], 0.8-8.7). The median cumulative alemtuzumab dose was 0.6 mg/kg (IQR, 0.6-1) administered over 2 to 7 days. A 2-compartment population pharmacokinetics model with parallel linear and nonlinear elimination including allometrically scaled bodyweight (median, 17.50 kg; IQR, 8.76-33.00) and lymphocyte count at baseline (mean, 2.24 × 109/L; standard deviation ± 1.87) as significant pharmacokinetic predictors was developed using nonlinear mixed effects modeling. Based on the model-estimated median concentration at day of HSCT (0.77 μg/mL; IQR, 0.33-1.82), patients were grouped into a low- (≤0.77 μg/mL) or high- (>0.77 μg/mL) exposure groups. High alemtuzumab exposure at day of HSCT correlated with delayed CD4+ and CD8+ T-cell reconstitution (P value < .0001) and increased risk of GF (P value = .043). In contrast, alemtuzumab exposure did not significantly influence the incidence of aGVHD grade ≥2, mortality, chimerism at 1 year, viral reactivations, and autoimmunity at a median follow-up of 3.3 years (IQR, 2.5-8.0). In conclusion, this novel population pharmacokinetics model is suitable for individualized intravenous precision dosing to predict alemtuzumab exposure in pediatric allogeneic HSCT for nonmalignant diseases, aiming at the achievement of early T-cell reconstitution and prevention of GF in future prospective studies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Achini-Gutzwiller FR, Schilham MW, von Asmuth EGJ, et al. Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study. Blood Adv. 2023. PMID: 37285798. doi:10.1182/bloodadvances.2022009051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。